Cargando…
Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis
BACKGROUND: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-γ1b (rIFN-γb) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. METHODOLOGY/PRINCIPA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737621/ https://www.ncbi.nlm.nih.gov/pubmed/19753300 http://dx.doi.org/10.1371/journal.pone.0006984 |
_version_ | 1782171453191356416 |
---|---|
author | Dawson, Rod Condos, Rany Tse, Doris Huie, Maryann L. Ress, Stanley Tseng, Chi-Hong Brauns, Clint Weiden, Michael Hoshino, Yoshihiko Bateman, Eric Rom, William N. |
author_facet | Dawson, Rod Condos, Rany Tse, Doris Huie, Maryann L. Ress, Stanley Tseng, Chi-Hong Brauns, Clint Weiden, Michael Hoshino, Yoshihiko Bateman, Eric Rom, William N. |
author_sort | Dawson, Rod |
collection | PubMed |
description | BACKGROUND: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-γ1b (rIFN-γb) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. METHODOLOGY/PRINCIPAL FINDINGS: We performed a randomized, controlled clinical trial of directly observed therapy (DOTS) versus DOTS supplemented with nebulized or subcutaneously administered rIFN-γ1b over 4 months to 89 patients with cavitary pulmonary tuberculosis. Bronchoalveolar lavage (BAL) and blood were sampled at 0 and 4 months. There was a significant decline in levels of inflammatory cytokines IL-1β, IL-6, IL-8, and IL-10 in 24-hour BAL supernatants only in the nebulized rIFN-γ1b group from baseline to week 16. Both rIFN-γ1b groups showed significant 3-fold increases in CD4+ lymphocyte response to PPD at 4 weeks. There was a significant (p = 0.03) difference in the rate of clearance of Mtb from the sputum smear at 4 weeks for the nebulized rIFN-γ1b adjuvant group compared to DOTS or DOTS with subcutaneous rIFN-γ1b. In addition, there was significant reduction in the prevalence of fever, wheeze, and night sweats at 4 weeks among patients receiving rFN-γ1b versus DOTS alone. CONCLUSION: Recombinant interferon-γ1b adjuvant therapy plus DOTS in cavitary pulmonary tuberculosis can reduce inflammatory cytokines at the site of disease, improve clearance of Mtb from the sputum, and improve constitutional symptoms. TRIAL REGISTRATION: ClinicalTrials.gov NCT00201123 |
format | Text |
id | pubmed-2737621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-27376212009-09-15 Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis Dawson, Rod Condos, Rany Tse, Doris Huie, Maryann L. Ress, Stanley Tseng, Chi-Hong Brauns, Clint Weiden, Michael Hoshino, Yoshihiko Bateman, Eric Rom, William N. PLoS One Research Article BACKGROUND: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-γ1b (rIFN-γb) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. METHODOLOGY/PRINCIPAL FINDINGS: We performed a randomized, controlled clinical trial of directly observed therapy (DOTS) versus DOTS supplemented with nebulized or subcutaneously administered rIFN-γ1b over 4 months to 89 patients with cavitary pulmonary tuberculosis. Bronchoalveolar lavage (BAL) and blood were sampled at 0 and 4 months. There was a significant decline in levels of inflammatory cytokines IL-1β, IL-6, IL-8, and IL-10 in 24-hour BAL supernatants only in the nebulized rIFN-γ1b group from baseline to week 16. Both rIFN-γ1b groups showed significant 3-fold increases in CD4+ lymphocyte response to PPD at 4 weeks. There was a significant (p = 0.03) difference in the rate of clearance of Mtb from the sputum smear at 4 weeks for the nebulized rIFN-γ1b adjuvant group compared to DOTS or DOTS with subcutaneous rIFN-γ1b. In addition, there was significant reduction in the prevalence of fever, wheeze, and night sweats at 4 weeks among patients receiving rFN-γ1b versus DOTS alone. CONCLUSION: Recombinant interferon-γ1b adjuvant therapy plus DOTS in cavitary pulmonary tuberculosis can reduce inflammatory cytokines at the site of disease, improve clearance of Mtb from the sputum, and improve constitutional symptoms. TRIAL REGISTRATION: ClinicalTrials.gov NCT00201123 Public Library of Science 2009-09-15 /pmc/articles/PMC2737621/ /pubmed/19753300 http://dx.doi.org/10.1371/journal.pone.0006984 Text en Dawson et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Dawson, Rod Condos, Rany Tse, Doris Huie, Maryann L. Ress, Stanley Tseng, Chi-Hong Brauns, Clint Weiden, Michael Hoshino, Yoshihiko Bateman, Eric Rom, William N. Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis |
title | Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis |
title_full | Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis |
title_fullStr | Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis |
title_full_unstemmed | Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis |
title_short | Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis |
title_sort | immunomodulation with recombinant interferon-γ1b in pulmonary tuberculosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737621/ https://www.ncbi.nlm.nih.gov/pubmed/19753300 http://dx.doi.org/10.1371/journal.pone.0006984 |
work_keys_str_mv | AT dawsonrod immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT condosrany immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT tsedoris immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT huiemaryannl immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT ressstanley immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT tsengchihong immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT braunsclint immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT weidenmichael immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT hoshinoyoshihiko immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT batemaneric immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis AT romwilliamn immunomodulationwithrecombinantinterferong1binpulmonarytuberculosis |